Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) - Research analysts at HC Wainwright reduced their Q3 2024 EPS estimates for shares of Dianthus Therapeutics in a research note issued to investors on Monday, August 12th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn ($0.53) per share for the quarter, down from their previous estimate of ($0.33). HC Wainwright has a "Buy" rating and a $40.00 price objective on the stock. The consensus estimate for Dianthus Therapeutics' current full-year earnings is ($2.18) per share. HC Wainwright also issued estimates for Dianthus Therapeutics' Q4 2024 earnings at ($0.73) EPS, FY2024 earnings at ($2.33) EPS, Q1 2025 earnings at ($0.81) EPS, Q2 2025 earnings at ($0.90) EPS, Q3 2025 earnings at ($0.82) EPS, Q4 2025 earnings at ($0.83) EPS, FY2025 earnings at ($3.36) EPS, FY2026 earnings at ($4.49) EPS, FY2027 earnings at ($4.88) EPS and FY2028 earnings at ($3.72) EPS.
Several other brokerages have also recently commented on DNTH. Lifesci Capital upgraded Dianthus Therapeutics to a "strong-buy" rating in a report on Tuesday, June 11th. Baird R W upgraded shares of Dianthus Therapeutics to a "strong-buy" rating in a research report on Friday, July 26th. Robert W. Baird started coverage on shares of Dianthus Therapeutics in a research note on Friday, July 26th. They set an "outperform" rating and a $58.00 target price for the company. Cantor Fitzgerald began coverage on shares of Dianthus Therapeutics in a research report on Thursday, June 27th. They set an "overweight" rating on the stock. Finally, Wedbush decreased their price target on Dianthus Therapeutics from $38.00 to $36.00 and set an "outperform" rating for the company in a report on Friday, August 9th. Eight research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $44.71.
View Our Latest Analysis on Dianthus Therapeutics
Dianthus Therapeutics Stock Performance
Shares of DNTH traded up $2.03 during mid-day trading on Wednesday, reaching $28.50. 126,486 shares of the company were exchanged, compared to its average volume of 193,266. The business has a 50 day simple moving average of $26.65 and a two-hundred day simple moving average of $25.24. The stock has a market capitalization of $836.45 million, a PE ratio of -4.89 and a beta of 1.89. Dianthus Therapeutics has a 52 week low of $6.58 and a 52 week high of $33.77.
Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.01). The company had revenue of $1.86 million during the quarter, compared to analyst estimates of $0.63 million.
Institutional Investors Weigh In On Dianthus Therapeutics
Several hedge funds and other institutional investors have recently bought and sold shares of DNTH. Tower Research Capital LLC TRC acquired a new position in shares of Dianthus Therapeutics during the fourth quarter worth approximately $25,000. SG Americas Securities LLC bought a new stake in Dianthus Therapeutics during the 2nd quarter valued at $112,000. American Century Companies Inc. increased its stake in Dianthus Therapeutics by 38.6% during the 2nd quarter. American Century Companies Inc. now owns 30,432 shares of the company's stock valued at $788,000 after purchasing an additional 8,473 shares in the last quarter. WINTON GROUP Ltd acquired a new position in Dianthus Therapeutics during the second quarter worth $265,000. Finally, Point72 DIFC Ltd bought a new position in shares of Dianthus Therapeutics in the second quarter valued at $334,000. 47.53% of the stock is owned by institutional investors.
Dianthus Therapeutics Company Profile
(
Get Free Report)
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Featured Stories
![Earnings History and Estimates for Dianthus Therapeutics (NASDAQ:DNTH)](https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&Symbol=DNTH)
Before you consider Dianthus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dianthus Therapeutics wasn't on the list.
While Dianthus Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.